Walter J. Scott, MD, James Shepherd, MS, Sanjiv Sam Gambhir, MD, PhD

Slides:

Advertisements

Similar presentations

Comparison of Endobronchial Ultrasound and/or Endoesophageal Ultrasound with Transcervical Extended Mediastinal Lymphadenectomy for Staging and Restaging.

Advertisements

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma Kemp H Kernstine, MD, PhD, William Stanford, MD, Brian F Mullan,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Current Guidelines for the Management of Small Cell Lung Cancer

Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography Walter.

Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer Masato.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Comparison of Endobronchial Ultrasound and/or Endoesophageal Ultrasound with Transcervical Extended Mediastinal Lymphadenectomy for Staging and Restaging.

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Sarcoid-Like Reaction Mimics Progression of Disease After Induction Chemotherapy for Lung Cancer Masayuki Chida, MD, PhD, Takashi Inoue, MD, Koichi Honma,

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients.

Cooperative Group Clinical Trials in General Thoracic Surgery: Report From the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical.

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

The True False Negative Rates of Esophageal and Endobronchial Ultrasound in the Staging of Mediastinal Lymph Nodes in Patients With Non-Small Cell Lung.

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

Cost-Effectiveness of Initial Diagnostic Strategies for Pulmonary Nodules Presenting to Thoracic Surgeons Stephen A. Deppen, MA, MS, William T. Davis,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma Timothy E Sawyer, MD, James A Bonner, MD, Perry M Gould,

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Mark K Ferguson, MD, Amy G Lehman, BA The Annals of Thoracic Surgery

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports

Thymic and Mediastinal Lymph Node Metastasis of Colon Cancer

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Accuracy of Fluorodeoxyglucose-Positron Emission Tomography Within the Clinical Practice of the American College of Surgeons Oncology Group Z4031 Trial.

Nicholas W. Choong, MD, Robert S. Hellman, MD

Lewis Y antigen expression and postoperative survival in non–small cell lung cancer Fumihiro Tanaka, MD, Ryo Miyahara, MD, Yohsuke Ohtake, MD, Kazuhiro.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

11C-Acetate and 18F-Fluorodeoxyglucose Positron Emission Tomography of Pulmonary Adenocarcinoma Masahiro Kaji, MD, PhD, Hiroaki Nomori, MD, PhD, Kenichi.

Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Kemp H Kernstine, MD, PhD, Kelley A McLaughlin,

Beware the malignant jellyfish

Menopausal effects on presentation, treatment, and survival of women with non–small cell lung cancer Kimberly A Moore, MD, Carlos M Mery, MD, MPH, Michael.

Edwin van Velzen, MD, Aart Brutel de la Rivière, MD, PhD, Hans J

An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Aritoshi Hattori, MD, Kenji Suzuki, MD

Who should decide margin length in pulmonary excision of lung cancer?

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Mark I. Block, MD The Annals of Thoracic Surgery

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography Kwhanmien Kim, MD, Seung Joon Park,

Meghan R. Flanagan, MD, Thomas K. Varghese, MD, MS, Leah M

Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography Michael B Wallace, MD, James Ravenel, MD, Mark I Block,

Presentation transcript:

Cost-effectiveness of FDG-PET for staging non–small cell lung cancer: a decision analysis Walter J. Scott, MD, James Shepherd, MS, Sanjiv Sam Gambhir, MD, PhD The Annals of Thoracic Surgery Volume 66, Issue 6, Pages 1876-1884 (December 1998) DOI: 10.1016/S0003-4975(98)01055-8

Fig 1 Decision tree showing the four strategies analyzed (A to D). Square represents a decision node; circles are chance nodes; and triangles are terminal nodes. (Bx = biopsy; CT = computed tomography; NSCLC = non–small cell lung carcinoma; PET = positron emission tomography.) The Annals of Thoracic Surgery 1998 66, 1876-1884DOI: (10.1016/S0003-4975(98)01055-8)

Fig 2 Incremental cost-effectiveness ratio (ICER) analysis over a range of positron emission tomography (PET) Medicare reimbursement values with CT plus PET strategies (B to D) compared with the baseline strategy A. Alternative strategies with a negative ICER dominate strategy A. Horizontal line marks $50,000 per life-year saved, the threshold value below which an alternative strategy is considered to be cost-effective. The Annals of Thoracic Surgery 1998 66, 1876-1884DOI: (10.1016/S0003-4975(98)01055-8)

Fig 3 Incremental cost-effectiveness ratio (ICER) analysis over a range of prevalence values for metastasis with CT plus PET strategies (B to D) compared with the baseline strategy A. Horizontal line as in Figure 2. The Annals of Thoracic Surgery 1998 66, 1876-1884DOI: (10.1016/S0003-4975(98)01055-8)